University of Exeter spin-out Neuronostics win prestigious national award

Neuronostics, which researches the use of AI to enhance diagnosis and treatment of epilepsy, secured the ‘Start-Up Award’ at the Medilink UK Healthcare Business Awards 2020, announced on Thursday.

The company had been awarded the regional title by Medilink South West earlier this year.

Speaking after the event, co-founder and CEO Professor John Terry said: “I was amazed that we won, having seen the strength of competition in our category. There were some very strong contenders from all around the country.

“It’s been a real team effort and wouldn’t have been possible without the tireless work of our senior team.  We’re currently undertaking a commercial fund raise, so we can accelerate our route to market and ensure that our technologies are being used in the clinic and at home for the benefit of people with epilepsy as soon as possible.”

Neuronostics was co-founded by Professor Terry and Dr Wessel Woldman in 2018. Their research is focused on the development and application of mathematical and computational methodologies for understanding the dynamics of biomedical systems, with particular interests in the transitions between healthy and unhealthy states in the human brain.

Medilink South West, who awarded Neuronostics with their regional title, added:“We are delighted that Neuronostics are the winners of the highly competitive and prestigious Start Up Award at the Medilink UK Healthcare Business Awards 2020. We were blown away by the standard of their application back in February, when we awarded them the regional award in the same category.

“This is a huge achievement for the company and it’s great to see their continued success, after another recent achievement - a total of £870,000 in NIHR-funded AI in Health and Care Award grants for the continued development of their innovative BioEP technology.”

Neuronostics’ first clinical product #BioEP gives a risk score of epilepsy, through computer analysis of brain data that is routinely collected clinically as part of the diagnostic process.

The company are keen to hear from partners including EEG hardware and software manufacturers, clinical and academic researchers, as well as potential investors.